Liang Yu1, Zhong-Jie Sun, Sheng-Li Wu, Cheng-En Pan. 1. Department of Hepatobiliary Surgery, First Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China. yuliang@163.com
Abstract
AIM: To study the antitumour activity of resveratrol and its effect on the expression of cell cycle proteins including cyclin D1, cyclin B1 and p34cdc2 in transplanted liver cancer of murine. METHODS: Murine transplanted hepatoma H22 model was used to evaluate the in vivo antitumor activity of resveratrol. Following abdominal administration of resveratrol, the change in tumour size was recorded and the protein expression of cyclin D1, cyclin B1 and p34cdc2 in the tumor and adjacent noncancerous liver tissues were measured by immunohistochemistry. RESULTS: Following treatment of H22 tumour bearing mice with resveratrol at 10 or 15 mg/kg bodyweight for 10 days, the growth of murine transplantable liver cancer was inhibited by 36.3% or 49.3%, respectively. The inhibitory effect was significant compared to that in control group (P<0.05). The level of expression of cyclin B1 and p34cdc2 protein was decreased in the transplantable murine hepatoma 22 treated with resveratrol whereas the expression of cyclin D1 protein did not change. CONCLUSION: Resveratrol exhibits anti-tumour activities on murine hepatoma H22. The underlying anti-tumour mechanism of resveratrol might involve the inhibition of the cell cycle progression by decreasing the expression of cyclinB1 and p34cdc2 protein.
AIM: To study the antitumour activity of resveratrol and its effect on the expression of cell cycle proteins including cyclin D1, cyclin B1 and p34cdc2 in transplanted liver cancer of murine. METHODS:Murine transplanted hepatoma H22 model was used to evaluate the in vivo antitumor activity of resveratrol. Following abdominal administration of resveratrol, the change in tumour size was recorded and the protein expression of cyclin D1, cyclin B1 and p34cdc2 in the tumor and adjacent noncancerous liver tissues were measured by immunohistochemistry. RESULTS: Following treatment of H22 tumour bearing mice with resveratrol at 10 or 15 mg/kg bodyweight for 10 days, the growth of murine transplantable liver cancer was inhibited by 36.3% or 49.3%, respectively. The inhibitory effect was significant compared to that in control group (P<0.05). The level of expression of cyclin B1 and p34cdc2 protein was decreased in the transplantable murinehepatoma 22 treated with resveratrol whereas the expression of cyclin D1 protein did not change. CONCLUSION:Resveratrol exhibits anti-tumour activities on murinehepatoma H22. The underlying anti-tumour mechanism of resveratrol might involve the inhibition of the cell cycle progression by decreasing the expression of cyclinB1 and p34cdc2 protein.
Authors: M Sato; P S Ray; G Maulik; N Maulik; R M Engelman; A A Bertelli; A Bertelli; D K Das Journal: J Cardiovasc Pharmacol Date: 2000-02 Impact factor: 3.105
Authors: Joanne Young; Melissa Barker; Leigh Fraser; Michael D Walsh; Kevin Spring; Kelli G Biden; John L Hopper; Barbara A Leggett; Jeremy R Jass Journal: Pathology Date: 2002-12 Impact factor: 5.306
Authors: Mohammad Athar; Jung Ho Back; Xiuwei Tang; Kwang Ho Kim; Levy Kopelovich; David R Bickers; Arianna L Kim Journal: Toxicol Appl Pharmacol Date: 2007-01-03 Impact factor: 4.219
Authors: Ole Vang; Nihal Ahmad; Clifton A Baile; Joseph A Baur; Karen Brown; Anna Csiszar; Dipak K Das; Dominique Delmas; Carmem Gottfried; Hung-Yun Lin; Qing-Yong Ma; Partha Mukhopadhyay; Namasivayam Nalini; John M Pezzuto; Tristan Richard; Yogeshwer Shukla; Young-Joon Surh; Thomas Szekeres; Tomasz Szkudelski; Thomas Walle; Joseph M Wu Journal: PLoS One Date: 2011-06-16 Impact factor: 3.240
Authors: Katarzyna Kupisiewicz; Patrice Boissy; Basem M Abdallah; Frederik Dagnaes Hansen; Reinhold G Erben; Jean-Francois Savouret; Kent Søe; Thomas L Andersen; Torben Plesner; Jean-Marie Delaisse Journal: Calcif Tissue Int Date: 2010-09-15 Impact factor: 4.333